$DARE

Daré Bioscience reported a Q1 2026 net loss of approximately $3 million on revenue of $152,455, primarily from R&D services and royalties. The company highlighted upcoming revenue milestones in 2026 and 2027 from product launches like Flora Sync LF5 and DARE to PLAY, while also advancing its pipeline with positive interim Phase 3 results for Ovaprene and ARPA-H funded DARE-HPV. Daré aims to build a multi-product revenue profile to complement its grant funding and equity financings.